两种免疫途径制备的肠道病毒71型兔血清抗体效价比较  

Titers of rabbit antisera against enterovirus 71 prepared by two immunization routes

作　　者：胡云光[1] 沈冬[1] 李亚东[1] 杨晓蕾[1] 洪超[1] 付杰 王玺[1] HU Yun-guang;SHEN Dong;LI Ya-dong;YANG Xiao-lei;HONG Chao;FU Jie;WANG Xi(Institute of Medical Biology Chinese Academy of Medical Sciences,Kunming 650118,Yunnan Province,China)

机构地区：[1]中国医学科学院医学生物学研究所,云南昆明650118

出　　处：《中国生物制品学杂志》2019年第1期91-94,共4页Chinese Journal of Biologicals

摘　　要：目的比较两种免疫途径制备的肠道病毒71型(enterovirus 71,EV71)兔血清抗体效价。方法将EV71灭活疫苗原液分别经皮下及肌内注射途径免疫两组家兔,每组5只,剂量均为5μg/只,两组均分别于0、7、14及28 d各免疫1次,初次免疫抗原与等量弗氏完全佐剂充分混合,后续免疫抗原与等量弗氏不完全佐剂充分混合。两组均于初次免疫前及每次免疫后7 d经家兔耳缘动脉采血,分离血清,检测血清中和抗体效价。结果两种免疫注射途径均可诱导家兔产生较高的抗体效价,7只家兔血清抗体效价均> 1∶10 000,皮下注射组有3只,肌内注射组有4只;肌内注射组血清抗体效价整体优于皮下注射组,在初次免疫后第21天时尤其明显(P <0. 05)。结论肌内注射途径制备的兔血清抗体效价高于皮下注射,本实验为今后制备高效价血清抗体提供了参考。Objective To compare the titers of rabbit antisera against enterovirus 71(EV71) prepared by two immunization routes.Methods Two groups of rabbits,five for each,were immunized with inactivated EV71 vaccine by subcutaneous and intramuscular routes respectively,each at a dosage of 5 μg,on days 0,7,14 and 18.The antigen for the first dose was mixed well with an equal volume of complete Freund adjuvant,while those for the following doses with incomplete Freund adjuvant.Serum samples were collected before immunization and 7 d after each dose,and determined for neutralizing antibody titer.Results High antibody titers were induced by both subcutaneous and intramuscular routes.The antibody titers of more than 1 ∶ 10 000 were induced in seven rabbits,three in subcutaneous immunization group and four in intramuscular immunization group.The antibody titers induced by intramuscular route were higher than those by subcutaneous route,especially those on day 21 after the first dose(P< 0.05).Conclusion The titer of rabbit antisera prepared by intramuscular route was higher than that by subcutaneous route, which provided a reference for the preparation of high titer rabbit antiserum against EV71.

关 键 词：肠道病毒71型 灭活疫苗 肌内注射 皮下注射 血清抗体效价 

分 类 号：R373.2[医药卫生—病原生物学] R392-33[医药卫生—基础医学]